We specialize in hard to find items
All Categories
Schatzberg's Manual of Clinical Psychopharmacology
Share Tweet
*Price and Stocks may change without prior notice
*Packaging of actual item may differ from photo shown
- Electrical items MAY be 110 volts.
- 7 Day Return Policy
- All products are genuine and original
About Schatzberg's Manual Of Clinical Psychopharmacology
Product Description The Manual of Clinical Psychopharmacology has been the leading resource for the clinical use of psychiatric medications for more than 30 years. Now in its ninth edition, the manual continues to offer thoroughly updated, exhaustively vetted, and evidence-based information on psychotropic drugs in a collegial, conversational style that both training and practicing clinicians will find useful and authoritative. To ensure that the ever-expanding number of available agents with widening indications receives proper coverage, the authors have continued their effort to cull or condense coverage of less commonly used agents (e.g., barbiturates) in favor of more recently approved drugs (e.g., VMAT-2 inhibitors for tardive dyskinesia, pimavanserin) and those whose approval by the U.S. Food and Drug Administration (FDA) appears imminent. This approach has helped to maintain a user-friendly size, and the volume's logical structure makes information easy to locate on the fly, a boon to busy practitioners. The authors devote an entire chapter, new to this edition, to important developments in laboratory-guided pharmacotherapy, including pharmacogenomic testing, neurocognitive testing, quantitative EEG, and neuroimaging. Its ease of use, accessible style, and evidence-based content have helped to elevate Schatzbergs Manual of Clinical Psychopharmacology to the well-deserved stature of a classic, which no mental health clinician should be without. Review This is an excellent, evidence-based review of current treatments. The information is presented in a way that is clinically relevant and useful. This manual is a worthy resource for any training or practicing psychiatrists, as well as other clinicians.--Michael Easton, M.D. "Doody's Book Review " From the Inside Flap The Manual of Clinical Psychopharmacology has been the leading resource for the clinical use of psychiatric medications for more than 30 years. Now in its ninth edition, the manual continues to offer thoroughly updated, exhaustively vetted, and evidence-based information on psychotropic drugs in a collegial, conversational style that both training and practicing clinicians will find useful and authoritative. To ensure that the ever-expanding number of available agents with widening indications receives proper coverage, the authors have continued their effort to cull or condense coverage of less commonly used agents (e.g., barbiturates) in favor of more recently approved drugs (e.g., VMAT-2 inhibitors for tardive dyskinesia, pimavanserin) and those whose approval by the U.S. Food and Drug Administration (FDA) appears imminent. This approach has helped to maintain a user-friendly size, and the volume's logical structure makes information easy to locate on the fly, a boon to busy practitioners. The authors devote an entire chapter, new to this edition, to important developments in laboratory-guided pharmacotherapy, including pharmacogenomic testing, neurocognitive testing, quantitative EEG, and neuroimaging. Its ease of use, accessible style, and evidence-based content have helped to elevate Schatzberg's Manual of Clinical Psychopharmacology to the well-deserved stature of a classic, which no mental health clinician should be without. From the Back Cover The Manual of Clinical Psychopharmacology has been the leading resource for the clinical use of psychiatric medications for more than 30 years. Now in its ninth edition, the manual continues to offer thoroughly updated, exhaustively vetted, and evidence-based information on psychotropic drugs in a collegial, conversational style that both training and practicing clinicians will find useful and authoritative. To ensure that the ever-expanding number of available agents with widening indications receives proper coverage, the authors have continued their effort to cull or condense coverage of less commonly used agents (e.g., barbiturates) in favor of more recently approved drugs (e.g., VMAT-2 inhibitors
